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The curability of the majority of anal carcinomas using radio-
therapy, especially when administered in combination with
chemotherapy, has been convincingly demonstrated (Papillon
et al, 1974; Anonymous, 1996; Bartelink et al, 1997).
Abdominoperineal resection (APR) has consequently fallen into
disfavour in the initial management of this disease, particularly
since the anatomical advantage offered by sphincter-conserving
approaches is assumed to be associated with definite quality of life
(QOL) advantages. Beside the preservation of the anatomical
integrity of normal structures, QOL of patients surviving anal
cancer may be influenced by additional factors, including treat-
ment-related side-effects and the physiological function of the
preserved organs. Indeed, conservative approaches based on radio-
therapy, with or without chemotherapy, can be associated with
chronic complications that may significantly impair QOL.
Moreover, while major late complications that require APR or
diverting colostomy occur in less than 15% of treated patients
(Papillon et al, 1989; Touboul et al, 1994; Allal et al, 1997), pelvic
irradiation may potentially be associated with functional symp-
toms related to anorectal dysfunction in a more significant propor-
tion of cases (Sedgwick et al, 1994; Yeoh et al, 1996). QOL of
patients with certain pelvic malignancies has been assessed after
various treatment approaches (Gelber et al, 1996; Anderson and
Lutgendorf, 1997). However, there are thus far no published
reports concerning QOL outcome in patients treated with sphincter
conservation for anal carcinoma. The aim of this single-institution
cross-sectional study was to evaluate long-term QOL in patients
treated with such approaches and to try to identify factors that
might negatively affect QOL parameters.
PATIENTS AND METHODS
Patients characteristics
The study population was drawn from among 165 patients with
anal carcinoma who received sphincter-conserving treatment
using radiotherapy, with or without chemotherapy, between
January 1976 and December 1994 at the Geneva University
Hospital. All patients were considered for QOL assessment who
were 80 years old or less at the time of the study, and who were
alive without disease activity at least 3 years after completion of
treatment with a functioning anal sphincter. The maximum age
limit was chosen to avoid a significant impact of the comorbidities
on QoL, or on the validity of its assessment. Fifty-two patients
satisfied the inclusion criteria. Forty-nine patients were contacted
by telephone to solicit their participation, and three who had no
telephone number were contacted by mail. Forty-six patients gave
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their approval to participate in the study, one refused, two were
judged ineligible because of serious co-morbidities and the three
patients contacted by mail did not respond. Among the 46 patients
who received the two questionnaires, five refused to complete
them for different reasons (unclear, two; number of questions, two;
questions related to sexual aspects, one), leaving 41 (79%) patients
evaluable for the present analysis. Patient characteristics are
displayed in Table 1. The median follow-up time was 116 months
(range 37–218).
Treatment
Details of treatment techniques have been described in a previous
report (Allal et al, 1993). Eleven patients received radiotherapy
alone and 30 concomitant radiation and chemotherapy. In all cases
radiotherapy was delivered in two sequences. The first sequence
was designed to treat involved sites and the potential microscopic
involved areas and consisted of external beam radiotherapy
(EBRT) with 60 Co when Papillon’s technique was used (perineal
field ±sacral field), or with photons of 6MV or more when
antero-posterior opposed pelvic fields were used. The second
sequence ‘boost’ directed to the initial involved sites consisted of
brachytherapy in 31 patients and EBRT in ten. Radiotherapy treat-
ment details are displayed in Table 2.
Chemotherapy consisted in all cases of 5-fluorouracil (600–
800mg m–2 day–1 ´4) and Mitomycin-C (10mg m–2), except in
two instances where Mitomycin-C was replaced by leucovorin or
cisplatin. Generally, chemotherapy started on day 1 and consisted
of 1 cycle in 25 patients, 2 cycles in four patients and 3 cycles in
one patient. The doses of the different agents were adjusted
according to the age and general condition of the patients.
Before radiotherapy, six patients had an excisional biopsy and 3
an inguinal adenectomy. One patient who presented with a local
recurrence after radiotherapy was salvaged by a limited local
surgery. The remainder of the patients had not undergone any
surgical treatment for anal cancer.
QOL assessment
The assessment of QOL was performed by using two question-
naires developed by the QOL Study Group of the European
Organization for Research and Treatment of Cancer: a validated
questionnaire assessing cancer-specific QOL (EORTC QLQ-C30)
(Aaronson et al, 1993) and one assessing site-specific (colorectal)
QOL (EORTC QLQ-CR38), which is in the process of validation.
EORTC QLQ-C30
This is a patient self-rating questionnaire that comprises six multi-
item function scales measuring physical, role, social, emotional
and cognitive functions, and overall QOL. Separate symptom
scales are included to assess pain, fatigue and emesis, and five
single items to measure gastrointestinal symptoms, dyspnoea,
appetite loss and sleep disturbances. A final item evaluates the
perceived economic consequences of the disease.
EORTC QLQ-CR38
This module is a patient self-rating questionnaire that comprises
38 questions, of which 19 are completed by all patients and the
remaining by subset of patients (males or females; patients with or
without a stoma). The general structure comprises four multi-
item/single-function scales, seven multi-item symptom scales and
one single symptom item. The functional scales assess body
image, sexual functioning, sexual enjoyment and future perspec-
tive. The symptom scales assess radiotherapy side effects on
micturition, chemotherapy side-effects, gastrointestinal general
symptoms, defecation problems, stoma-related problems and
sexual dysfunction in males or females. The single symptom item
assesses weight loss. This module has been validated in The
Netherlands (Sprangers MAG, Velde te A, Aaronson NK, on
behalf of the European Organisation for Research and Treatment
of Cancer Study Group on Quality of Life. The construction and
testing of the EORTC Colorectal Cancer Specific Quality-of-Life
questionnaire Module QLQ-CR38, manuscript under review) and
is currently being used in a wide range of cross-cultural studies.
Two supplementary questions were added to the questionnaire
to assess the degree of satisfaction with anorectal function and
patients’ current preferences regarding treatment modalities
(conservative vs APR), taking into consideration the functional
outcome. The first question used an analogue scale from 1 (totally
dissatisfied) to 10 (totally satisfied). For the second question,
patients had the choice between three answers: 1 = I still prefer the
sphincter-conserving procedure; 2 = sometimes I think an APR
Table 1Patient characteristics
Parameters Number of patients
Median initial age, years (range)  60 (42–75)
Median actual age, years (range)  71 (55–80)




Cana l ±margin ±rectum  8
Histology
Keratinizing squamous  26
Basaloid and transitional  15





aAnal canal classification. bSix patients with inguinal nodes.
Table 2Characteristics of radiotherapy
Median dose/
fraction/days
Fields and doses (1st course)
AP/ PA pelvic fields (+ laterals)  32 (+2)  4 0 Gy/20/31
Perinea l ±sacral fields  7  30 Gy/10/20
Boost technique (2nd course)
(A) EB RT 10  20 Gy/10/12
Perineal field  5
AP/ PA ±lateral fields  3
Other techniques  2
(B) Interstitial brachytherapy  31
Median dose – median dose rate  20 Gy–7 8 cGy/h
Median interval between courses  39 days
Median total treatment duration  72 days1590 AS Allal et al
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might have been preferable; and 3 = I definitely think an APR
would have been preferable. In addition, by discussion with the
patient, anal sphincter function was evaluated according to the
Memorial Sloan-Kettering-Cancer Center anal function criteria
(MSK-AF) (Minsky et al, 1992). The score ‘excellent = 1’ corre-
sponds to 1–2 bowel movements per day and no soilage;
‘good = 2’ corresponds to 3–4 bowel movements per day and/or
mild soilage; ‘fair = 3’ corresponds to episodic >4 bowel move-
ments per day and/or moderate soilage and finally ‘poor = 4’
corresponds to incontinence. Late complications were classified
according to the RTOG grading system (Perez and Brady, 1992).
Statistical methods
All scores of the QLQ-C30 and QLQ-CR38 are linearly trans-
formed such that all scales range from 0 to 100. The higher scale
score represents a higher level of functioning for the six (QLQ-
C30) and four (QLQ-CR38) multi-item/single-function scales
and a higher level of symptomatology/problems for the
symptom/single-item scales. Missing values were calculated such
that if at least half the items from the scale had been completed,
it was assumed that the missing items would have values equal
to the average of those present items.
The Mann–Whitney U-test was used to assess for significant
differences in score medians between subgroups. A difference
with a P-value ≤0.05 was considered as significant. The choice of
a non-parametric test was based on the score distributions that
were restricted to the upper middle part of the functioning scales
and to the lower or middle parts of the symptom scales. All factors
studied, except gender, were selected to define groups of at least
ten patients. We hypothesized that at least some scores of the
various scales would vary between subgroups of patients
according to some clinical parameters commonly believed to
affect QOL such as age, gender, late complications or organ
dysfunction and time since treatment. However, for T-stage and
the two therapeutic factors (addition of chemotherapy, and type of
boost), the study was rather exploratory and no a priori hypotheses
were formulated. The Fisher’s exact test was used to assess the
relationship between the different factors.
Table 3 EORTC QLQ-C30 mean scale and single items scores for the
Geneva University Hospital (GUH) and the Danish Central Population
Register (DCPR) series
GUH series, n = 41 Women population-based
[Standard Deviation] sample, DCPR series
n = 608
Functional scales
Physical function 79.5 [22] 86 (80)a
Role function 85 [21] 88 (85)
Emotional function 77 [25] 77 (79)
Cognitive function 76 [23] 85 (82)
Social function 82 [28] 91 (91)
Global quality of life 71 [21] 72 (70)
Symptom scales
Fatigue 27 [22] 25 (29)
Pain 15 [21] 21 (24)
Nausea and vomiting 6 [15] 4 (4)
Single items
Dyspnoea 13 [22] 9.5 (11)
Sleep disturbance 23.5 [29] 23 (28)
Appetite loss 10 [19] 6 (7)
Diarrhoea 28 [36] 7 (7)
Constipation 15 [21] 8 (9)
Financial impact 15 [28] 7 (8)
aValue in the brackets are the scores for women aged 51–75 years.
Table 4 EORTC QLQ-C30: functional and symptom scale score means (s.d.) according to clinical and therapeutic factors
Factors Nb Patients Physical Role Emotional Social Overall quality Fatigue Pain
function function function function of life
Age (current)
≤71 21 85 (19) 86 (23) 72 (28) 82 (31) 69 (26) 27 (22) 14 (24)
>71 20 73 (23) 84 (19) 82 (19) 81 (25) 73 (15) 28 (22) 17 (19)
Gender
Female 35 80 (22) 86 (20) 78 (25) 82 (26) 73 (21) 27 (22) 15 (22)
Male 6 73 (20) 77 (25) 69 (17) 83 (40) 61 (18) 31 (20) 17 (21)
T stage
T1–2 24 77 (24) 84 (23) 81 (21) 82 (30) 74 (24) 27 (24) 13 (21)
T3–4 17 82 (18) 85 (18) 71 (28) 82 (24) 67 816) 28 (17) 18 (22)
Treatment stratégy
RT alone 11 72 (24) 80 (18) 72 (32) 86 (21) 73 (22) 25 (20) 23 (25)
RT + CT 30 82 (21) 86 (22) 79 (21) 80 (30) 70 (21) 28 (22) 13 (20)
RT plan
EBRT + brachytherapy 31 80 (21) 84 (22) 73 (25) 77 (30) 68 (22) 29 (23) 18 (23)
EBRT alone 10 76 (26) 88 (15) 88 (17) 96 (7) 80 (13) 21 (16) 7 (11)
Late complications
Grade 0–1 11 83 (21) 94 (15) 88 (15) 91 (17) 85 (15)* 20 (18) 11 (20)
Grade 2–4 30 78 (22) 81 (22) 73 (26) 79 (30) 66 (21) 30 (22) 17 (22)
MSK anal function score
Score 1 21 80 (23) 92 (13) 75 (28) 87 (21) 76 (22)* 25 (17) 17 (23)
Score 2–4 20 79 (22) 77 (25) 79 (20) 76 (33) 66 (19) 29 (25) 14 (20)
Follow-up (months)
≤116 21 78 (25) 82 (24) 84 (17) 83 (31) 72 (18) 26 (25) 11 (17)
>116 20 81 (19) 87 (17) 69 (29) 80 (24) 70 (24) 29 (18) 20 (25)
aP ≤ 0.05; s.d.: standard deviation; RT: Radiotherapy; CT: Chemotherapy; EBRT: External Beam RT; GI: Gastro-Intestinal; MSK: Memorial Sloan Kettering.QOL in anal cancer patients 1591
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RESULTS
EORTC QLQ-C30 scores
The general results for all patients are given in Table 3. The mean
scores of the scales that would potentially be affected by the
selected clinical and therapeutic parameters are displayed in
Table 4. The results are detailed according to the significance level
of the differences in the scores between subgroups or the clinical
relevance of certain findings. The physical function scale scores
did not differ significantly in the subgroups, although older
patients tended to report lower scores (P = 0.08). For the role func-
tion scale, while non-significant, the severity of late complications
and poor MSK anal function appeared to have a negative effect
(P = 0.08 for both). This score did not differ with the length of
follow-up. For the emotional and the social function scales, no
significant differences were noted between the different
subgroups. However, the overall quality of life score was signifi-
cantly affected by the severity of late complications (P = 0.005)
and the anal function score (P = 0.04). This score did not differ
with the current age categories or with the length of follow-up.
No significant differences were noted between subgroups
concerning the fatigue and pain symptom scales, particularly
according to the length of follow-up.
EORTC QLQ-CR38 scores
The general results for all patients are given in Table 5. The mean
values of the main scales scores are displayed in Table 6 according
to selected clinical and therapeutic factors. In the latter Table
only scales that would potentially be affected by the selected
parameters and that had a satisfactory response rate were selected.
Body image function score was significantly lower only in patients
with advanced T-stage (P = 0.003). For the future perspective
function scale, no significant differences were noted between
subgroups, while lower scores were reported in patients with
higher grade of late complications (P = 0.1). The sexual func-
tioning score was significantly lower only in advanced age
subgroup (P = 0.01). None of the functional scale scores seemed to
be influenced by the length of follow-up.
Micturition dysfunction symptom scores were significantly
higher in patients treated with a brachytherapy boost (P = 0.02)
and in patients with long follow-up (P = 0.02). No significant
differences in the scores of general gastrointestinal symptoms
Table 5 EORTC QLQ-CR38 mean functional scale and symptom scores
Scales Nb. patients Scores (s.d.)
Functional scales
Body image 41 74 (29)
Future perspective 41 62 (30)
Sexual functioning 40 13 (20)
Sexual enjoyment 8 66 (25)
Symptom scales
RT side-effects on micturition 41 28 (18)
Chemotherapy side-effects 30 16 (20)
General gastrointestinal 41 21 (17)
Defecation problems 41 18 (14)
Sexual dysfunction of males 6 66 (31)
Sexual dysfunction of females 8 18 (14)
Weight loss 41 5 (14)
RT: radiotherapy; s.d.: standard deviation.
Table 6 EORTC QLQ-CR38: functional and symptom scale score means (s.d.) according to clinical and therapeutic factors
Factors Nb. patients Body image Future Sexual Micturition General Defecation
perspective functioningb dysfunction GI symptoms problems
Age (current)
≤71 21 67 (32) 60 (31) 22 (23)a 24 (16) 21 (14) 21 (15)
>71 20 80 (25) 63 (30) 3 (9) 32 (20) 20 (20) 15 (11)
Gender
Female 35 74 (29) 62 (30) 13 (20) 28 (20) 21 (18) 17 (12)
Male 6 70 (34) 61 (33) 16 (21) 29 (9) 16 (14) 23 (22)
T stage
T1–2 24 85 (25)a 68 (30) 14 (20) 28 (15) 20 (17) 17 (15)
T3–4 17 58 (28) 53 (29) 13 (20) 27 (23) 22 (18) 19 (12)
Treatment stratégy
RT alone 11 74 (27) 69 (28) 10 (17) 25 (17) 21 (17) 15 (11)
RT + CT 30 73 (30) 59 (31) 14 (21) 29 (19) 20 (17) 19 (14)
RT plan
EBRT + brachytherapy 31 75 (28) 58 (30) 13 (19) 31 (19)a 22 (19) 21 (13)a
EBRT alone 10 69 (32) 73 (30) 13 (22) 17 (13) 16 (10) 10 (11)
Late complications
Grade 0–1 11 79 (31) 76 (21) 21 (23) 24 (14) 14 (14) 11 (9)a
Grade 2–4 30 72 (29) 57 (32) 10 (18) 29 (20) 23 (18) 21 (14)
MSK anal function score
Score 1 21 79 (26) 68 (23) 16 (21) 28 (16) 19 (14) 12 (10)a
Score 2–4 20 68 (32) 53 (35) 11 (19) 28 (21) 22 (20) 24 (14)
Follow-up (months)
≤116 21 78 (29) 68 (30) 13 (22) 21 (17)a 19 (15) 19 (17)
>116 20 69 (29) 55 (29) 13 (18) 35 (18) 22 (20) 18 (10)
aP ≤ 0.05; SD: Standard Deviation; RT: Radiotherapy; CT: Chemotherapy; EBRT: External Beam RT; GI: Gastro-Intestinal; MSK: Memorial Sloan Kettering;
b 40 patients analysed1592 AS Allal et al
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were noted between subgroups. Finally, a significant higher defe-
cation problems score was reported in patients treated with
brachytherapy for the boost (P = 0.03).
Seventy-one per cent of patients indicated a high degree of satis-
faction with their present ano-rectal function (score 7–10), 24% a
moderate satisfaction (score 4–6) and 5% a low satisfaction (score
1–3). Regarding treatment preference, despite suboptimal function
in some cases, 38 patients (93%) preferred their present status with
anal sphincter preserved, while 3 (7%) had at least thought of the
possibility that an APR might have been a better choice.
DISCUSSION
Although the potentially negative impact of APR on QOL has
been well studied in patients with rectal cancer (Williams and
Johnston, 1983; Sprangers et al, 1995), little is known about QOL
parameters in long-term survivors of anal carcinomas following
non-surgical sphincter-conserving treatment, despite the wide
acceptance of such approaches (Papillon, 1974; Nigro et al, 1974;
Anonymous, 1996). Recently, we reported that in this setting,
radiotherapy, with or without chemotherapy, may be associated
with an actuarial rate of serious late complications as high as 20%
at 8 years (Allal et al, 1997). Taking these results into considera-
tion, we undertook a study designed to allow formal assessment of
QOL in all patients less than 81 years of age apparently cured at
least 3 years post-treatment with an intact anal sphincter. We
succeeded in evaluating 79% of potentially eligible patients treated
in our institution, using current QOL methodology based on
cancer and site-specific questionnaires developed by the EORTC
QOL Study Group. The study population is small, and the cross-
sectional design precluded an assessment of the effect of treatment
on QOL in the individual patient, or of possible changes in QOL
as a function of time. Moreover, the patients were treated over
a long time period, and the treatments used were somewhat
heterogeneous, both regarding radiotherapy techniques and
chemotherapy administration. Nonetheless, this study represents a
first step in documenting long-term QOL in conservatively-treated
anal cancer patients, and may provide insight regarding clinical or
treatment factors that negatively influenced QOL parameters.
In the absence of pre-treatment baseline parameters, QOL
scores are frequently difficult to interpret. In this regard it may be
useful to compare the results obtained in study patients to those
determined in a general population. Taking into account that 85%
of the patients in our series were female, we compared our
patients’ scores from the EORTC QLQ-C30 questionnaire with
those reported by Klee et al (1997) in 608 Danish women
who served as a population-based sample for this questionnaire
(Table 3). Interestingly, while cognitive and social function
subscales were slightly lower in our patients, probably reflecting
their more advanced age, the other functional scales were similar,
including global QOL. The only symptom score that was found
clearly to be higher in the study patients was diarrhoea, with an
apparent threefold increase, reflecting the known association of
pelvic irradiation with potentially chronic small intestinal dysfunc-
tion (Yeoh et al, 1993). In contrast, the finding of a lower pain
symptom score in the study patients was unexpected. However,
this score was considered inappropriately high in the Danish
series, a finding attributed by the authors to a high prevalence of
certain active diseases in the population studied.
Despite the small number of study patients, and the potential
problem of multiple testing (possible significant differences due to
a type 1 error), we tried to identify subgroups of patients
(according to selected factors) reporting lower functional or higher
symptom scores. Among the clinical and therapeutic parameters
studied, the RTOG late complication grade and the MSK anal
function score were the factors that most significantly affect
certain QOL scores. Thus, as anticipated from our previous study
on late complications (Allal et al, 1997), patients presenting with
grade 2–4 complications or MSK-AF scores of 2–4 had signifi-
cantly lower scores for the overall QOL scale, and these two
factors also tended to negatively affect the role function subscale.
Moreover, the severity of late complications was associated with
a trend to have lower scores for emotional function (irritability
and depression) and a higher fatigue symptom score. Considering
the chronic aspects of late complications, particularly the irre-
versibility of anal dysfunction, it is plausible that these factors
impact negatively on patients’ daily activities and their overall
sense of well-being. Although any impact of the length of follow-
up must be interpreted with caution, since the scores were deter-
mined in different patients receiving non-identical treatments, it is
noteworthy that patients with long follow-up did not generally
exhibit different QOL profiles from those of patients treated more
recently. Nonetheless, one might speculate that the trend toward
lower emotional function scores in patients with long follow-up
might be a consequence of living for a longer time with chronic
complications. Regarding the possible influence of age on general
QOL parameters, older patients had similar profiles to those of
younger patients, with the exception of a lower physical function
score (P = 0.08).
No significant impact of treatment variables on general QOL
parameters could be demonstrated in the current study. This is not
surprising, given the small sample size and the multiple potential
interactions between patient-related factors, length of follow-up,
radiotherapy technique and chemotherapy administration. A multi-
variate analysis in a considerably larger patient population would
be required to reliably evaluate potential effects of treatment-
related variables on QOL. With these reservations in mind, it
should be mentioned that patients treated with radiotherapy alone,
as well as those patients having had a brachytherapy boost, tended
to report a higher pain symptom, and that patients having had
brachytherapy showed a trend toward lower scores for the
emotional and social function scales. Although we have not found
a brachytherapy boost in itself to cause more serious late compli-
cations, one can speculate that adjustments of radiotherapy para-
meters in patients receiving chemotherapy might account for fewer
symptomatic sequelae in long-term survivors. In fact, when radio-
therapy was used alone, external beam treatment was given with
higher dose per fraction (mean 2.43 Gy vs 1.96, for total doses of
36.4 Gy and 39 Gy respectively), and a higher brachytherapy dose
was applied (mean 22.5 Gy vs 18 Gy), compared with patients
having been treated with concomitant chemotherapy.
Since the site-specific EORTC QLQ-CR38 questionnaire has
only recently been validated in The Netherlands for colorectal
cancer patients, no meaningful comparisons with other data sets
could be provided. The current results (Table 5) have thus been
interpreted according to the magnitude of variations from the best
theoretical scores, namely 100 for the function scales, and 0 for the
symptom scales. Moreover, for some scales we tried to identify
factors that seemed to affect the scores (Table 6).
For the body image function scale, the mean score of 74 may be
judged as satisfactory, considering the potentially negative impact
of alterations in the ano-genital area on body image in bothQOL in anal cancer patients 1593
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females and males (Williams and Johnston, 1983). Patients with
stage T3–4 tumours had significantly lower scores, perhaps
reflecting a greater tissue volume affected by disease involvement
or treatment-related changes. Indeed, while not significant,
patients with T3–4 tumours tended to have more severe complica-
tions and/or anal dysfunction (data not shown). On the other hand,
younger patients (≤ 71 years) tended to have lower scores, perhaps
reflecting more preoccupation with their body image than older
patients. Combining these two factors, younger patients with T3–4
tumours had a markedly lower body image score (50) compared
with older patients with T1–2 tumours (93).
No significant differences were found between subgroups in the
future perspective scale score. However, patients with severe
complications and/or anal dysfunction had a non-significant trend
to have lower scores, and this score seemed to decrease with the
length of follow-up. Patients presenting with MSK-AF 2–4 and
longer follow-up (>116 months) had a lower score (45) compared
with the score (81) of patients with MSK-AF 1 and shorter follow-
up. This may reflect the negative effect of persistent complica-
tions, particularly chronic anal dysfunction, on the future
perspective score.
The sexual functioning score was dramatically low (13). Only
14 patients (35%) reported some sexual activity. Moreover, the
extent of this activity varied greatly among patients and never
reached the maximum level of functioning in any individual
patient. As expected older patients had a significantly lower
score compared with younger patients. Also a lower score was
observed in patients with severe late complications. Older patients
(>71 years) with grade 2–4 complications had a score of 1
compared with the score of 30 observed in younger patients with
grade 0–1 complications. Because genital organs are in close prox-
imity to the high-dose treatment volume, the high degree of sexual
dysfunction in the present series is in keeping with the results
observed in women with gynaecological cancers (Andersen et al,
1989) and men with prostate cancers (Crook et al, 1996), in whom
loss of sexual desire and/or orgasm, dyspareunia and loss of
potency are frequent. Sexual enjoyment function was reported by
only eight women, with the moderate score of 66, consistent with
the rather low sexual dysfunction symptom score (18) reported by
the women in this study. This is in contrast with the score reported
by men (66), reflecting a high degree of sexual dysfunction. The
latter score can be considered as surprising, since the nervi
erigentis and the pudendal nerve are generally not included in the
high dose volume, particularly when brachytherapy is used.
Moreover, in the absence of a population-based reference group, it
is difficult to determine to which extent the degree of sexual
dysfunction is due to treatment in these relatively aged patients.
The overall score for micturition symptom scale was quite high
(28) and was significantly higher in patients treated with a
brachytherapy boost and in patients with longer follow-up.
However, there was a significant relation between these two
factors, in that all patients with >116 months’ follow-up had
received brachytherapy. Since urinary tract complications may
become progressively symptomatic over long follow-up (Kapp et
al, 1997), it is unclear to what extent brachytherapy in itself truly
influences the micturition symptom score.
Considering that all patients received external beam pelvic irra-
diation, the overall score of 21 for general gastrointestinal symp-
toms seems acceptable. None of the factors studied significantly
influenced this score. Moreover, the score of 18 for defecation
problems can be considered as satisfactory, considering the tumour
site involved and the rather elderly population studied. As
expected RTOG complication grade and MSK-AF score were
significantly reflected in the defecation problem scale results
(these three parameters may explore the same symptoms). The
only treatment factor that significantly affected this score was the
use of a brachytherapy boost. While this may represent a real
effect, only ten patients were treated with EBRT boosts and their
follow-up was shorter. Finally, the weight loss symptom score was
very low (5), implying that weight loss is very unlikely to repre-
sent a main problem in successfully treated anal cancer patients.
In conclusion, to our knowledge the present study represents the
first report on long-term cancer and site-specific QOL in patients
treated conservatively by radiotherapy with or without
chemotherapy for anal carcinomas. The overall results obtained by
using the EORTC QLQ-C30 questionnaire were similar to those of
a population-based sample, except for diarrhoea that was observed
more frequently in treated anal cancer patients. On the other hand,
a clearly negative impact of late complications and/or anal
dysfunction on cancer-specific QOL was demonstrated, hence
emphasizing the importance of future research aiming at reducing
such side-effects. On the basis of the results obtained with the site-
specific module (EORTC QLQ-CR38), we conclude that the
different function scale scores appear acceptable, with the excep-
tion of the low sexual functioning score. In the symptom scale
scores gastrointestinal, defecation and micturition dysfunction
seemed acceptable, while the sexual dysfunction score was
surprisingly quite high, particularly in men. In this regard, while
the severity of late complications seems to have a negative impact
on some symptom scores, the impact of treatment-related factors
merits further exploration, particularly the technical aspects of
radiotherapy. For both questionnaires, none of the function and
symptom scale scores seem to be improved in patients with longer
follow-up. Finally, it is noteworthy that, despite suboptimal anal
function in nearly 50% of patients, 71% of patients expressed
a high satisfaction with their present anorectal function and only
7% even considered the possibility that APR might have been a
preferable approach.
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